SAN RAMON, Calif.--(BUSINESS WIRE)--Nextrials, Inc., a leader in clinical research software and services, today announced that its flagship Prism® clinical trial management software was used by Allon Therapeutics Inc. (TSX: NPC) to successfully manage and analyze results of a Phase IIa trial of a novel treatment for Alzheimer’s disease. Using the Prism software, results from Allon’s nine-month, 16-site clinical trial were announced in less than seven weeks after the final patient visit — a notable achievement within the biopharmaceutical R&D community.
